Claims

1. A solid pharmaceutical composition suitable for oral administration, comprising
   a) a first compound selected from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a pharmaceutically acceptable salt thereof, and a phosphate derivative thereof,
   b) a filler, and
   c) a stabilizer comprising a cyclodextrin or a derivative thereof.

2. A composition according to claim 1, comprising less than 1.5% or 1% by weight, e.g. 0.25% by weight or less, of the first compound, based on the total weight of the composition.

3. A composition according to claim 1, comprising 0.5mg or less, of the first compound,

4. A composition according to any preceding claim, wherein the filler comprises a sugar alcohol, for example mannitol.

5. A composition according to any preceding claim, further comprising a binder, for example a binder comprising hydroxypropyl cellulose.

6. A composition according to any preceding claim, further comprising a lubricant, for example a lubricant comprising magnesium stearate.

7. A composition according to any preceding claim, wherein the stabilizer comprises hydroxypropyl-beta -cyclodextrin.

8. A composition according to any preceding claim, wherein the first compound is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

9. A composition according to any preceding claim for treating an autoimmune disease.

10. A method of treating an autoimmune disease in a patient in need thereof, comprising administering a therapeutically effective amount of a compound selected from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a pharmaceutically acceptable salt thereof, and a phosphate derivative thereof, with a pharmaceutical composition as defined in any one of claims 1 to 8.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A solid pharmaceutical composition suitable for oral administration, comprising
   a) a first compound selected from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a pharmaceutically acceptable salt thereof, and a phosphate derivative thereof,
   b) a filler, and
   c) a stabilizer against the inducement of degradation products comprising a cyclodextrin or a derivative thereof.

2. A composition according to claim 1, comprising less than 1.5% or 1% by weight, e.g. 0.25% by weight or less, of the first compound, based on the total weight of the composition.

3. A composition according to claim 1, comprising 0.5mg or less, of the first compound.

4. A composition according to any one of the preceding claims, wherein the filler comprises a sugar alcohol, for example mannitol.

5. A composition according to any one of the preceding claims, further comprising a binder, for example a binder comprising hydroxypropyl cellulose.

6. A composition according to any one of the preceding claims, further comprising a lubricant, for example a lubricant comprising magnesium stearate.

7. A composition according to any one of the preceding claims, wherein the stabilizer comprises hydroxypropyl-beta -cyclodextrin.

8. A composition according to any one of the preceding claims, wherein the first compound is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

9. A composition according to any one of the preceding claims for treating an autoimmune disease.

10. Use of a solid pharmaceutical composition according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of an autoimmune disease.